Data becomes valuable when outside teams can see the next decision
Kenvue and Allergan Aesthetics show why evidence packaging matters: study type, boundary, population, and claim use need to be organized before data can support action.
Data becomes valuable when outside teams can see the next decision.
Around AAD 2026, many companies released public research updates. The difference was not only who published more. It was who made the results easier for outside teams to use.
Kenvue’s public materials organized 20 research abstracts across healthy aging, moisturization, sun protection, and acne. That structure matters because it reduces interpretation cost. A brand team, R&D group, physician, or partner can more quickly see which line has public support, which signal is still early, and which claim should not be overextended.
Allergan Aesthetics’ public materials made a different boundary visible. Clinical results for repeat TrenibotE treatment and survey data on GLP-1-related aesthetics behavior were both useful, but they were not the same type of evidence. Separating clinical outcomes from survey insight helps keep safety, efficacy, and market-understanding claims in their proper lanes.
For technical teams, this is not only communications polish. When data has to serve external claims, partnership review, regulatory discipline, and R&D decisions, organization becomes part of the evidence package.
For N1 Life, the same rule applies to delivery and formulation materials. Study design, population, duration, model boundary, endpoint, and claim scope should be visible early enough for a partner to know what the data can support.
The scarce capability is not publishing more data. It is turning data into material that lets an external team judge the next step.